Experimental vaccination strategies, such as those using Flt3-L expressing B16 melanoma cells, demonstrate higher levels of CD8+ T cell and DC infiltration compared to vaccination with GM-CSF-expressing tumor cells [165]. The gene discussed is FLT3LG; the disease is neoplasm.